kit

Abstract

The present disclosure relates to a kit. The kit of the present disclosure comprises: a kit body comprising a needle tube and a needle, the first end of the needle being mounted to the needle tube; and a catabolic filling thread comprising a first segment and a second segment connected to each other, at least a part of the first segment being located inside the needle, and at least a part of the second segment being located outside the needle, wherein the catabolic filling thread is a thread made of poly-L-lactic acid. The kit of the present disclosure comprises a catabolic filling thread which can be composed of poly-L-lactic acid, is absorbable, has no residue, and is metabolized into lactic acid in the human body. Such a configuration makes the catabolic filling thread itself not only play a role in filling and tightening when filling surgery is performed using the catabolic filling thread of the present disclosure, but also the lactic acid after its metabolism can still stimulate fibroblasts in the skin and subcutaneous tissue to reconstruct the collagen framework in the human body by using fibroblasts.

Description

Technical Field

[0001] This disclosure relates to the field of medical aesthetic materials technology, and in particular to a reagent kit. Background Technology

[0002] With social development and improved living standards, people's pursuit of beauty is increasing, which places higher demands on the related technologies and materials in the field of cosmetic medicine. For example, in terms of filler and firming, the number of people starting to try it is increasing, and the areas requiring filler procedures are also rising.

[0003] In related technologies, the injection of filler materials can cause certain trauma to human tissues and has postoperative side effects, resulting in a poor user experience. Summary of the Invention

[0004] To overcome the problems existing in the related technologies, this disclosure provides a reagent kit.

[0005] According to a first aspect of the present disclosure, a reagent kit is provided, comprising: a reagent kit body including a syringe and a needle, wherein a first end of the needle is attached to the syringe; and a catabolic filling line including a first segment and a second segment connected to each other, wherein at least a portion of the first segment is located inside the needle and at least a portion of the second segment is located outside the needle, wherein the catabolic filling line is a line made of poly-L-lactic acid.

[0006] In one embodiment, the length of the catabolic filler line is 20-80 mm.

[0007] In one embodiment, the needle is 20-50 mm in length.

[0008] In one embodiment, the length of the needle is 35-40 mm; the length of the catabolic filling line inside the needle is 28-33 mm, and the length of the catabolic filling line outside the needle is 10-28 mm.

[0009] In one embodiment, the length of the needle is 22-27 mm; the length of the catabolic filling line inside the needle is 15-20 mm, and the length of the catabolic filling line outside the needle is 5-20 mm.

[0010] In one embodiment, the diameter of the catabolic filler line is 90-200 μm.

[0011] In one embodiment, the molecular weight of the poly-L-lactic acid in the first segment is less than the molecular weight of the poly-L-lactic acid in the second segment, and a connecting segment is provided between the first segment and the second segment, the connecting segment being located inside the needle.

[0012] In one embodiment, the length of the connecting segment is 0.5mm-5mm.

[0013] In one embodiment, the diameter of the catabolic filler line is 100-120 μm.

[0014] In one embodiment, the surface of the catabolic filler line is smooth.

[0015] In one embodiment, the kit further includes a fixation element fitted onto the needle for securing the catabolic filling line.

[0016] In one embodiment, the distance between the fixing member and the second end of the needle is 5-10 mm, and the second end is disposed opposite to the first end.

[0017] In one embodiment, the kit further includes a seal, with the kit body and the catabolic filler line located inside the seal.

[0018] According to a second aspect of the present disclosure, a catabolic filler line is provided, the catabolic filler line being composed of poly-L-lactic acid, the poly-L-lactic acid having a molecular weight of 30,000 Da-150,000 Da.

[0019] In one embodiment, the poly-L-lactic acid has a molecular weight of 30,000 Da or 60,000 Da.

[0020] In one embodiment, the catabolic filler thread has a diameter of 90-200 μm and is used for implantation at the junction of the dermis and subcutaneous tissue in the human body.

[0021] In one embodiment, the catabolic filler line is colorless or pale white.

[0022] In one embodiment, the tensile strength of the catabolic filler thread is 25CN-45CN.

[0023] In one embodiment, the elongation of the catabolic filler line is 25%-40%.

[0024] According to a second aspect of the present disclosure, a method for preparing a catabolic filler yarn is provided, the method comprising: dehydrating and drying poly-L-lactic acid and then spinning it to obtain a catabolic filler yarn after yarn extrusion; and stretching and cooling the catabolic filler yarn to obtain a catabolic filler yarn.

[0025] In one embodiment, the step of dehydrating and drying poly-L-lactic acid and then spinning it to obtain a decomposition and metabolic filler yarn includes: dehydrating and drying poly-L-lactic acid; spinning the dried poly-L-lactic acid at a temperature of 190-220°C, and obtaining a decomposition and metabolic filler yarn after spinning.

[0026] In one embodiment, the dehydration and drying of poly-L-lactic acid includes: dehydrating and drying the poly-L-lactic acid at a temperature of 65-110°C for 16-24 hours.

[0027] In one embodiment, the dehydration and drying of poly-L-lactic acid includes: dehydrating and drying the poly-L-lactic acid in a blower drying oven.

[0028] In one embodiment, the step of stretching and cooling the catabolic filler filament to obtain the catabolic filler wire includes: stretching the catabolic filler filament to a diameter of 100-120 μm; and cooling and shaping the stretched catabolic filler filament into a catabolic filler wire.

[0029] In one embodiment, stretching the catabolic filler filament into a catabolic filler filament with a diameter of 100-120 μm includes: stretching the catabolic filler filament into a catabolic filler filament with a diameter of 100-120 μm at a temperature of 70-85°C, wherein the stretching speed is 2-4 times the filament output speed.

[0030] This disclosure also provides a catabolic filler thread, which is a thread composed of poly-L-lactic acid with a molecular weight of 30,000 Da-150,000 Da, and has a diameter of 90-200 μm. The catabolic filler thread is used for implantation into the dermis of the human body.

[0031] In one embodiment, the diameter of the catabolic filler line is 100-180 μm.

[0032] In one embodiment, the diameter of the catabolic filler line is 100-150 μm.

[0033] In one embodiment, the diameter of the catabolic filler line is 110-130 μm.

[0034] In one embodiment, the molecular weight of the catabolic filler line is 50,000 Da to 130,000 Da.

[0035] In one embodiment, the molecular weight of the catabolic filler line is 60,000 Da to 120,000 Da.

[0036] In one embodiment, the molecular weight of the catabolic filler line is 80,000 Da to 100,000 Da.

[0037] In one embodiment, the catabolic filler thread is a thread that is absorbed after 7 months of implantation in the human body.

[0038] In one embodiment, the catabolic filler line is a line obtained by dehydrating, drying, and stretching the poly-L-lactic acid.

[0039] The technical solutions provided by the embodiments of this disclosure can include the following beneficial effects: The kit of this disclosure includes a catabolic filler thread composed of poly-L-lactic acid, which is absorbable, leaves no residue, and is metabolized in the human body to form lactic acid. This design allows the catabolic filler thread to not only provide a filling and tightening effect when used for filler procedures, but also enables the metabolized lactic acid to stimulate fibroblasts in the skin and subcutaneous tissue, thereby utilizing fibroblasts to rebuild the collagen framework in the body, thus providing a long-lasting and continuous filling and tightening effect.

[0040] This disclosure improves the user experience by placing a portion of the catabolic filling line inside the needle and another portion outside the needle, which facilitates the operator's operation.

[0041] It should be understood that the above general description and the following detailed description are exemplary and explanatory only, and are not intended to limit this disclosure. Attached Figure Description

[0042] The accompanying drawings, which are incorporated in and form a part of this specification, illustrate embodiments consistent with this disclosure and, together with the description, serve to explain the principles of this disclosure.

[0043] Figure 1 This is a schematic diagram of a catabolic filling line according to an exemplary embodiment.

[0044] Figure 2 This is a schematic diagram illustrating the usage state of a catabolic filler line according to an exemplary embodiment.

[0045] Figure 3 This is a flowchart illustrating a method for preparing a catabolic filler line according to an exemplary embodiment.

[0046] Figure 4 This is a flowchart illustrating a method for preparing a catabolic filler line according to an exemplary embodiment.

[0047] Figure 5 This is a flowchart illustrating a method for preparing a catabolic filler line according to an exemplary embodiment.

[0048] Figure 6This is a flowchart illustrating a method for preparing a catabolic filler line according to an exemplary embodiment.

[0049] Figure 7 This is a flowchart illustrating a method for preparing a catabolic filler line according to an exemplary embodiment.

[0050] Figure 8 This is a flowchart illustrating a method for preparing a reagent kit according to an exemplary embodiment.

[0051] Figure 9 This is a flowchart illustrating a method for preparing a reagent kit according to an exemplary embodiment. Detailed Implementation

[0052] Exemplary embodiments will now be described in detail, examples of which are illustrated in the accompanying drawings. When the following description relates to the drawings, unless otherwise indicated, the same numerals in different drawings denote the same or similar elements. The embodiments described in the following exemplary embodiments do not represent all embodiments consistent with this disclosure. Rather, they are merely examples of apparatuses and methods consistent with some aspects of this disclosure as detailed in the appended claims.

[0053] With social development and improved living standards, people's pursuit of beauty is increasing, which places higher demands on the related technologies and materials in the field of cosmetic medicine. For example, in terms of filler and firming, the number of people starting to try it is increasing, and the areas requiring filler procedures are also rising.

[0054] In related technologies, the decomposition and metabolic filling threads used can cause certain trauma to human tissues and have postoperative side effects, resulting in a poor user experience.

[0055] To overcome the problems existing in the related technologies, this disclosure provides a reagent kit.

[0056] The kit provided in this disclosure includes: a kit body including a syringe and a needle, a first end of the needle being attached to the syringe; and a catabolic filling line, a portion of which is located inside the needle and another portion of which is located outside the needle, wherein the catabolic filling line is a line made of poly-L-lactic acid.

[0057] The catabolic filling line disclosed herein may include a first segment and a second segment connected to each other, wherein at least a portion of the first segment is located inside the needle and at least a portion of the second segment is located outside the needle.

[0058] The kit disclosed herein includes a catabolic filler thread composed of poly-L-lactic acid, which is absorbable, leaves no residue, and is metabolized in the human body to form lactic acid. This design allows the catabolic filler thread to not only provide a firming and filling effect when used in filler procedures, but also enables the metabolized lactic acid to stimulate fibroblasts in the skin and subcutaneous tissue, thereby promoting collagen reconstruction and providing a long-lasting and continuous firming effect. Furthermore, by placing a portion of the catabolic filler thread inside the needle and another portion outside, the kit facilitates operation and improves the user experience.

[0059] Figure 1 This is a schematic diagram of a catabolic filling line according to an exemplary embodiment. Figure 2 This is a schematic diagram illustrating the usage state of a catabolic filler line according to an exemplary embodiment.

[0060] like Figure 1 and Figure 2 As shown, the reagent kit 10 of this disclosure may include a reagent kit body and a catabolic filling line 200. The reagent kit body may include a syringe 300 and a needle 100. One end of the needle 100 may be attached to the syringe 300. For example, one end of the needle 100 may be inserted into the syringe 300. The syringe 300 and the needle 100 may be interconnected, and the syringe 300 may also be provided with a cooperating piston, piston shaft, and piston handle to complete the injection of the reagent kit 10. Alternatively, the syringe 300 may be provided with a core rod, and the injection of the reagent kit 10 can be completed by pushing and pulling the core rod.

[0061] In one embodiment, the length of the catabolic filler line 200 can be 20-80 mm. For example, in an embodiment, the length of the catabolic filler line 200 can be 20 mm, 25 mm, 30 mm, 35 mm, 40 mm, 45 mm, 50 mm, 55 mm, 60 mm, 65 mm, 70 mm, 75 mm, or 80 mm.

[0062] In one embodiment, the length of the needle 100 is 20-50 mm. For example, in an embodiment, the length of the needle 100 can be 20 mm, 25 mm, 30 mm, 35 mm, 38 mm, 40 mm, 45 mm, or 50 mm.

[0063] like Figure 1 and Figure 2As shown, part of the catabolic filler suture 200 can be located inside the needle 100, and another part can be located outside the needle 100. This design facilitates the doctor's operation; that is, during use, it is not necessary to push out part of the catabolic filler suture before injection, but can be injected directly. While facilitating the doctor's operation, it also reduces the possibility of contamination during use. Specifically, the more complicated the operation steps, the greater the possibility of contamination.

[0064] In one embodiment, the length of the needle 100 can be 35-40 mm, the length of the catabolic filling line 200 inside the needle 100 can be 28-33 mm, and the length of the catabolic filling line 200 outside the needle 100 can be 10-28 mm. For example, in one embodiment, the length of the needle 100 can be 38 mm, the length of the catabolic filling line 200 inside the needle 100 can be 30 mm, and the length of the catabolic filling line 200 outside the needle 100 can be 25 mm.

[0065] In one embodiment, the length of the needle 100 can be 22-27 mm, the length of the catabolic filling line 200 inside the needle 100 is 15-20 mm, and the length of the catabolic filling line 200 outside the needle 100 is 5-20 mm. For example, in one embodiment, the length of the needle 100 can be 25 mm, the length of the catabolic filling line 200 inside the needle 100 is 18 mm, and the length of the catabolic filling line 200 outside the needle 100 is 18 mm.

[0066] It should be noted that this disclosure is not limited thereto. The specific reagent kit 10, needle 100, catabolic filling line 200, and the length of the catabolic filling line 200 outside and inside the needle 100 are not limited to the above embodiments and can be adjusted differently depending on the injection site.

[0067] like Figure 1 and Figure 2 As shown, the catabolic filler line 200 provided in this disclosure can be composed of poly-L-lactic acid, that is, the composition of the catabolic filler line of this disclosure is 100% poly-L-lactic acid.

[0068] In recent years, numerous medical studies have elucidated that lactic acid is a crucial factor in regulating and activating fibroblasts in the skin and soft tissues, and that fibroblasts play a major role in rebuilding the supporting framework of the skin and subcutaneous tissue—the collagen microstructure. Therefore, the catabolic filler thread disclosed in this invention, after being implanted in the human body, also stimulates collagen production when it is metabolized into lactic acid. In contrast, catabolic filler threads in related technologies do not produce lactic acid during metabolism and therefore do not stimulate collagen production.

[0069] Therefore, the metabolic filler thread disclosed herein, after implantation into the human body, in addition to its filling and firming effect, after being metabolized into lactic acid, can also be evenly distributed to the skin and soft tissues, thereby triggering the reconstruction of the autologous collagen structure and achieving an autologous filling effect. That is, lactic acid stimulates the body to produce collagen, and the collagen produced can play a filling role.

[0070] In this disclosure, the molecular weight of poly-L-lactic acid can be between 30,000 Da and 150,000 Da. For example, in one embodiment, the molecular weight of poly-L-lactic acid can be 30,000 Da. In another embodiment, the molecular weight of poly-L-lactic acid can be 60,000 Da.

[0071] In this disclosure, the tensile strength of the catabolic filler thread can be 2.0-4.0 cN / dtex (25CN-45CN).

[0072] Based on the above, the catabolic filler thread disclosed herein is composed of poly-L-lactic acid. After being injected into the human body, the poly-L-lactic acid is metabolized into lactic acid. Lactic acid stimulates fibroblasts to generate collagen, thereby achieving a firming effect. In this case, the tensile strength requirements for the catabolic filler thread can be reduced, thus simplifying the manufacturing process and making it easier to produce catabolic filler threads composed of poly-L-lactic acid, thereby improving the production efficiency of catabolic filler threads.

[0073] In this disclosure, reducing the tensile strength of the catabolic filler thread can prevent excessive tensile forces from being generated in certain locations (such as around the eyes, neck, and face), thus avoiding damage to the human tissue in these areas. On the other hand, reducing the tensile strength can prevent the catabolic filler thread from pulling on the tissues in these areas, which would lead to relaxation of these tissues after the catabolic filler thread is metabolized, thereby reducing the duration of the effect of the catabolic filler thread composed of poly-L-lactic acid.

[0074] It should also be noted that, in this disclosure, the length of the needle 100, the length of the catabolic filler 200 inside the needle 100, and the length of the catabolic filler 200 outside the needle 100 are set specifically for the catabolic filler 200 used in this disclosure, which has relatively low tensile strength. That is, this setting can be coordinated with the tensile strength of the catabolic filler 200, allowing for convenient injection without damaging the 200.

[0075] The catabolic filling line disclosed herein may include a first segment and a second segment connected to each other, wherein at least a portion of the first segment is located inside the needle and at least a portion of the second segment is located outside the needle.

[0076] Poly-L-lactic acid (PLLA) degrades into lactic acid in human tissues. Lactic acid stimulates fibroblasts in these tissues to rebuild the collagen microstructure, a crucial step in renewing human skin and subcutaneous tissue. Therefore, PLALA is not the direct active ingredient when it works in the human body. The effectiveness of PLALA depends on the total amount of lactic acid it can degrade into. The molecular weight of PLALA affects the degradation rate; smaller molecular weights degrade faster, and vice versa.

[0077] The rate of lactic acid release can be controlled by controlling the molecular weight. Therefore, for the same weight of poly-L-lactic acid, i.e., the same final total effect, poly-L-lactic acid with a smaller molecular weight has a higher short-term effect but a shorter release time. Higher molecular weight has a lower short-term effect but a longer duration of effect. In this disclosure, the catabolic filler line is set into two segments, namely the first segment and the second segment, and the first segment and the second segment use different molecular weights. This setting allows for controllability so that some segments (the first segment or the second segment) have a rapid release effect in the initial stage, while some segments (the second segment or the first segment) have a slow release effect over a long period of time.

[0078] It should be noted that this disclosure is not limited to including the first and second paragraphs; in some cases, it may include more paragraphs, and the molecular weights of these paragraphs may be different from each other.

[0079] In this disclosure, at least a portion of the first segment may be located inside the needle, and at least a portion of the second segment may be located outside the needle. For example, in some embodiments, the first segment may be entirely located inside the needle, and the second segment may be located outside the needle. In such embodiments, the molecular weight of the poly-L-lactic acid in the first segment may be smaller than the molecular weight of the poly-L-lactic acid in the second segment.

[0080] This design, due to the larger molecular weight of the poly-L-lactic acid in the second segment, can prevent the catabolic filler thread located outside the needle from being catalyzed by factors such as moisture in the air, thus avoiding partial breakage of the thread during operation.

[0081] In this disclosure, the second segment can be located outside the needle tip, and also includes the folded portion of the needle tip, such as the second end of the needle. During operation, the needle tip (the second end of the needle) contacts and punctures the skin first upon insertion, thus the force exerted on the needle tip is relatively large. Using a second segment with a larger molecular weight of poly-L-lactic acid at the needle tip can prevent the suture from breaking when the needle tip enters the skin.

[0082] Larger molecular weight threads degrade faster under the same environmental conditions. Conversely, smaller molecular weight threads degrade more quickly in vivo. Generally, even if the environment is dried during product packaging, a small amount of moisture inevitably remains in the air and within the finished product packaging. If this moisture causes the threads to become brittle, some threads may break during operation, especially at the needle tip where the thread bends back. Therefore, this disclosure allows for the placement of high molecular weight threads at the needle tip bend, reducing the chance of thread breakage when the needle is inserted into the skin. Simultaneously, it enables rapid degradation of a small amount within the needle, resulting in quick post-operative effects, while the high molecular weight threads provide a delayed and sustained release of their effects—a combined benefit.

[0083] In this disclosure, there may be a connecting segment between the first segment and the second segment, and the connecting segment may be located at the second end of the needle, with the second end being positioned opposite to the first end.

[0084] In this disclosure, the connecting segment can be located inside the needle. The connecting segment is the point where two segments of thread with different molecular weights of poly-L-lactic acid are joined. Compared to other parts of the calcitonin-filled thread, the connecting segment may be coarser. Placing it inside the needle can reduce pain experienced by the user during operation and improve the user experience.

[0085] For connections between poly-L-lactic acid (PLL) threads of different molecular weights, an end-to-end connection is optimal. To minimize pain during needle and thread insertion, two threads of different molecular weights are not used side-by-side, as this would increase pain due to the increased thread diameter. Furthermore, this design conceals the joint end of the two threads within the needle body, avoiding increased friction with the skin due to a relatively rougher connection point.

[0086] In this disclosure, the length of the connecting segment can be 0.5mm-5mm. For example, in one embodiment, the length of the connecting segment can be 1mm-3mm. In this disclosure, the connecting segment can be made of medical bio-adhesive, for example, α-cyanoacrylate, or other medical bio-adhesives such as SUP-SDBS composite.

[0087] In this disclosure, poly-L-lactic acid with different molecular weights (10000-130 kDa) can be used, and two or more segments with different molecular weights can be joined end to end with medical bio-adhesive. In this example, α-cyanoacrylate is used, but other medical bio-adhesives such as SUP-SDBS complex can also be used to join segments with different molecular weights.

[0088] In exemplary embodiments of this disclosure, the diameter of the catabolic filler thread can be 90-200 μm, and it can be implanted at the junction of the dermis and subcutaneous tissue. Because the diameter of the catabolic filler thread is relatively thin, it can be prevented from being visible on the skin surface when implanted at the junction of the dermis and subcutaneous tissue. Specifically, if the diameter of the catabolic filler thread exceeds this range, it may be directly visible from the user's skin surface, which reduces the aesthetic effect and fails to meet the customer's requirements.

[0089] Furthermore, the diameter of the metabolic filler thread disclosed herein is relatively thin, resulting in less stimulation to human tissues during implantation and less noticeable foreign body sensation for the user.

[0090] Specifically, the catabolic filler thread disclosed herein has a relatively thin diameter, allowing it to be implanted at the junction of the dermis and subcutaneous tissue. Fibroblasts are primarily located in the dermis; therefore, implanting the catabolic filler thread at this junction allows for better stimulation of fibroblasts by metabolized lactic acid, leading to collagen production and thus a more effective filling effect.

[0091] In this disclosure, the diameter of the catabolic filler thread is relatively thin, so that when implanted into the dermis, the outline of the catabolic filler thread will not be seen or felt on the user's skin surface.

[0092] Furthermore, because the catabolic filler threads of this application are relatively thin, the amount of poly-L-lactic acid per unit area of ​​the human body is relatively small after implantation. Therefore, the effective dose can be evenly distributed across the entire face, for example, different doses of catabolic filler threads can be injected into different locations on the face. However, if the diameter of the thread exceeds the range of this application, scarring may occur due to problems such as excessive local dosage, uneven dosage distribution, ineffective metabolites (PDO, PPDO threads), failure to change skin texture, or excessive local irritation.

[0093] In this disclosure, the catabolic filler thread can be colorless or off-white to avoid it being visible on the skin's surface. Specifically, if the catabolic filler thread is too dark, it may be directly visible from the user's skin, thus reducing the aesthetic effect and failing to meet the client's requirements.

[0094] In the exemplary embodiments of this disclosure, the surface of the catabolic filler thread can be smooth. This design reduces friction between the catabolic filler thread and human tissue during the filler tightening procedure, making it easier to inject the thread into the body. It also reduces pain during injection, improving the user experience. Furthermore, once inside the body, it does not cause damage, does not increase pain, and eliminates the risk of postoperative side effects.

[0095] Specifically, after the smooth catabolic filler thread is injected into the human body, it remains inside for a certain period of time. With the body's movements or facial expressions, the catabolic filler thread moves along with the surrounding tissues. In this situation, the smooth catabolic filler thread does not exert any pulling effect on the body's tissues; therefore, the user will not experience pain due to pulling, thus avoiding disruption to their daily life.

[0096] Poly-L-lactic acid is metabolized in the human body to form lactic acid, which is also present in the human body. The catabolic filler thread disclosed herein is 100% composed of poly-L-lactic acid, meaning that after implantation, the catabolic filler thread can be completely metabolized into lactic acid, and ultimately into carbon dioxide and water, achieving zero residue in the human body and improving the safety of the product disclosed herein.

[0097] For example, the catabolic filler thread disclosed herein can be metabolized and absorbed by the human body within approximately 6 months or 7 months after implantation. This disclosure does not specify a particular absorption time; in practice, the metabolic absorption time of the catabolic filler thread may vary depending on its diameter, implantation length, and implantation site.

[0098] In summary, the catabolic filler thread disclosed herein, composed of poly-L-lactic acid, not only fills the body to achieve a firming effect, but also stimulates fibroblasts to generate collagen through the lactic acid produced by poly-L-lactic acid metabolism, thereby further enhancing the firming effect. Furthermore, the generated collagen also acts as a filler. This design reduces the damage to the body caused by the catabolic filler thread while achieving both firming and filling effects. Moreover, as the catabolic filler thread metabolizes, its filling and firming effects can be sustained and long-lasting.

[0099] In summary, it can be seen that the reagent kit disclosed herein is easy to use. This disclosure places the catabolic filling line inside the needle, allowing for direct injection without the need for adding physiological saline or water for injection, or lidocaine injection solution. This not only saves a significant amount of time required for reconstitution (some dosage forms require reconstitution the day before, with a minimum of six hours required), but also reduces potential drug contamination during the preparation process.

[0100] The kit disclosed herein is pre-programmed with a precise injection volume. When the needle is continuously punctured into the treatment area, the catabolic filler line left in the target tissue has a certain volume, i.e., a "fixed dose" of poly-L-lactic acid, and each needle in the kit has a certain width. Therefore, within a certain area, only a safe dose of catabolic filler line can be inserted, thus eliminating the side effects of excessive local injection dosage that may occur due to poor control during liquid poly-L-lactic acid injection.

[0101] Specifically, different reagent kits can be prepared specifically for different injection sites and injection areas. During the procedure, doctors simply inject multiple kits according to the pre-calculated dosage to complete the operation. This avoids various irregularities and uncertainties that can occur with manual calculations and procedures.

[0102] The reagent kit disclosed herein has a simpler and more precise composition. Liquid facial rejuvenation injections require the addition of thickeners (such as CMC), lyophilized excipients (mannitol), and lidocaine anesthetics during the manufacturing process, increasing the risk of drug allergies or irritation. This disclosure completely removes all additives, containing only high-purity poly-L-lactic acid, thus eliminating the possibility of side effects caused by non-core components. Furthermore, traditional facial rejuvenation injections, after reconstitution, are turbulent liquids that begin to precipitate after a certain period of time (some formulations as short as twenty seconds), easily leading to the common problem of injecting the same amount of liquid but resulting in different dosages. The thread of this invention contains only a fixed amount of poly-L-lactic acid, allowing for completely precise control of the desired dosage per unit tissue volume.

[0103] In the exemplary embodiments of this disclosure, the diameter R of the catabolic filler line can be 100-120 μm. However, this disclosure is not limited to this, and different choices can be made as needed in actual use.

[0104] In this disclosure, catabolic filler threads can be applied to various parts of the human body, such as the face, torso, or buttocks. Specifically, different diameter catabolic filler threads can be selected depending on the application area. For example, catabolic filler threads used on the face can be relatively thin, such as approximately 90µm, 100µm, 110µm, or 120µm. Catabolic filler threads used on the buttocks can have a relatively thicker diameter, such as approximately 150µm, 160µm, 170µm, 180µm, 190µm, or 200µm. Figure 2 As shown, in actual use, the catabolic filler suture can be implanted using a kit. For example, the catabolic filler suture 200 can be pushed out of the needle tip 100 by pushing the needle tube 300 of the kit. The catabolic filler suture 200 located outside the kit can be fixed by a retainer 400. In this disclosure, the retainer 400 can be foam or silicone, or can be made of foam or silicone. In one embodiment, the retainer 400 can be a foam-like silicone sponge.

[0105] In this disclosure, the fixation member 400 can be fitted onto the needle 100 to fix the catabolic filler 200. For example, a notch can be provided on the fixation member 400 so that the catabolic filler 200 can be wrapped around the fixation member 400. By fixing the catabolic filler 200 with the fixation member 400, the catabolic filler 200 can be set more stably, so that the length of the catabolic filler 200 inside and outside the needle 100 remains unchanged. Thus, the accuracy of the doctor during the injection process can be further guaranteed.

[0106] In this disclosure, the distance L between the fixing member 400 and the second end of the needle 100 can be 5-10 mm. For example, in one embodiment, the distance L can be 10 mm. In this disclosure, the distance L is set within this range so that the fixing member 400 can fix the decomposition and metabolic filling line 200 while avoiding the fixing member 400 from affecting subsequent injections.

[0107] In this disclosure, the second end of the needle 100 is positioned opposite to the first end, meaning the injection end of the needle 100 can be the second end. The second end of the needle 100 can have a certain bevel, which facilitates injection.

[0108] In one embodiment, the kit 10 may further include a seal (not shown), within which both the kit body and the catabolic filling line 100 may be located. For example, the seal may be made of any material suitable for sterilization processes, specifically plastic or rubber. The seal may be at least partially transparent or opaque. A transparent seal facilitates observation of the internal kit body and needles, etc.

[0109] The sealed design allows the reagent kit to be pre-sterilized and packaged, and can be used immediately upon opening. It eliminates the need for adding physiological saline or water for injection, as well as lidocaine injection, before injection. This not only saves a significant amount of time required for reconstitution (some dosage forms require reconstitution the day before, with a minimum requirement of six hours), but also reduces potential drug contamination during the compounding process.

[0110] In this disclosure, the needle 100 may also be provided with a needle protective sleeve to protect the needle 100 from external contamination and to prevent the needle 100 from pricking others.

[0111] The setup disclosed herein, by designing the smooth catabolic filling line to be pre-placed inside and outside the needle tube through the bevel of the needle tip, allows the operator to simply remove the sterile inner packaging and needle sheath without the need for local anesthesia. The operation can be completed by directly puncturing and removing the needle tube with an extremely fine needle (30G~25G). Each placement of the line takes approximately 2 to 5 seconds.

[0112] According to the design disclosed herein (a complete set of sutures and flexible fine needles), the operator only needs simple training and can receive treatment repeatedly as many times as needed by the patient. This completely eliminates the discomfort and postoperative side effects caused by the old surgical methods that relied on extensive hooking and mechanical traction of soft tissue.

[0113] Specifically, the design disclosed herein can be divided into two parts: the first part utilizes the slender, flexible needle disclosed herein, which, upon insertion of the needle, triggers sensory neural network receptors along the dermis, causing numerous arrector pili muscles to contract, resulting in immediate skin contraction. Because this contraction effect is a three-dimensional volume reduction composed of numerous small planes contracting along the X and Y axes, it represents a substantial improvement over traditional thread lifting, which relies on unidirectional linear traction (with the experimental skin length remaining constant) on soft tissue, similar to the principle of drawing curtains. This physiological stimulation-induced uniform skin contraction can last for approximately three to five weeks.

[0114] The latter part of this disclosed design primarily relies on the degradation of poly-L-lactic acid (PLA) threads after approximately two to three weeks, releasing nano-sized lactic acid that diffuses into the surrounding tissues, including the dermis and subcutaneous tissue. This activates fibroblasts, begins to metabolize aging tissue, rebuilds a youthful collagen microstructure, and secretes autologous hyaluronic acid. This fosters the regeneration of other normal, healthy blood vessels, nerve endings, immune cells, and fat cells, establishing a fully functional, healthy, and firm youthful tissue. Compared to traditional methods that rely on coarser, non-functional materials like PDO and mechanical, uniaxial traction, the old traction methods not only fail to improve skin texture but also cause irreversible damage due to continuous mechanical pulling over time, leading to the breakage of skin and soft tissue fibers and further aging the appearance. Consequently, patient acceptance is extremely low. The design of this disclosed method improves the patient's user experience.

[0115] Using 30 subjects who used the catabolic filler thread of this disclosure as an example, and using 30 subjects who used implanted threads with barbs and a diameter larger than that of the catabolic filler thread of this application as a comparative example, the examples and comparative examples were tested in the following aspects:

[0116] 1. Regarding satisfaction, the study examines the number of participants willing to undergo a second treatment at the same price six months to one year later. In practice, the effects of such injections typically last for a certain period, not lifelong; therefore, participants often require multiple injections. For this reason, whether participants are willing to undergo the injection again at the same price within a certain timeframe is a crucial indicator of their satisfaction with the first treatment.

[0117] In the example, 25 subjects underwent a second procedure at the same price six months to one year later, while in the comparative example, only one subject underwent a second procedure at the same price six months to one year later. It can be seen that the subjects' satisfaction with this product was significantly higher than their satisfaction with using other implanted threads.

[0118] 2. Regarding comfort, the catabolic filling thread disclosed in this invention has a smaller diameter, meaning it is thinner. This reduces operational pain and achieves more uniform dosage distribution, shortening the degradation time. After degradation, the subject experiences less foreign body sensation, thus improving comfort.

[0119] In one example, only two subjects could feel or touch the threads within three days of the procedure. In a comparative example, 27 subjects could still feel the threads three months after the procedure, 12 subjects could still feel the threads six months later, and 7 subjects could still feel hard lumps in the threads nine months later.

[0120] 3. Regarding side effects, in the example, only two subjects experienced a slight protrusion on their cheek due to facial expressions after the procedure, which was painless and disappeared spontaneously within a week without treatment. In the comparative example, six subjects experienced problems requiring multiple debridement procedures due to one end of the suture protruding from the skin, and another seven subjects experienced varying degrees of visible changes in appearance due to suture tension caused by facial expressions.

[0121] 4. Regarding postoperative recovery speed, in the example, all 30 subjects resumed their normal cleansing routine, makeup, and skincare product use within two days after the procedure. In the example, all 30 subjects experienced no more slight swelling within three days post-procedure, and no visible bruising was observed after ten days. In the comparative example, 16 subjects reported swelling, pain, or bruising one month post-procedure.

[0122] Based on the same concept, this disclosure can provide a method for preparing a catabolic filler line, which can be used to fabricate the catabolic filler line in the above embodiments. Figure 3 This is a flowchart illustrating a method for preparing a catabolic filler line according to an exemplary embodiment, such as... Figure 3 As shown, the preparation method of this disclosure may include the following steps:

[0123] S11: Poly-L-lactic acid is dehydrated and dried before spinning, and after spinning, a decomposition and metabolic filler yarn is obtained.

[0124] S12: The catabolism filler wire is stretched and cooled to obtain the catabolism filler wire.

[0125] This disclosure employs a melt spinning process, placing poly-L-lactic acid microparticles / powder into a melt extruder. Through screw melt extrusion and stretching after filament extrusion, the resulting poly-L-lactic acid compact decomposition and metabolic filling yarn has high strength, uniform and fine diameter, and causes less damage to the tissue, thereby achieving a better compact filling effect.

[0126] In exemplary embodiments of this disclosure, Figure 4 This is a flowchart illustrating a method for preparing a catabolic filler line according to an exemplary embodiment, such as... Figure 4 As shown, the preparation method of this disclosure may include the following steps:

[0127] S21: Dehydrate and dry poly-L-lactic acid.

[0128] In this disclosure, poly-L-lactic acid can be dehydrated and dried using a forced-air drying oven.

[0129] S22: The dried poly-L-lactic acid is spun at a temperature of 170-220℃, and after spinning, a decomposition and metabolism filler yarn is obtained.

[0130] In this disclosure, for example, poly-L-lactic acid raw material can be dehydrated and dried before being added to a melt spinning machine. The melt spinning process involves placing poly-L-lactic acid microparticles / powder into a melt extruder and spinning at a melt spinning temperature of 170-220°C. Specifically, the extrusion method can also be set as extrusion, such as screw extrusion. In this disclosure, extrusion can be performed at room temperature.

[0131] S23: The catabolic filler wire is stretched and cooled to obtain the catabolic filler wire.

[0132] In this disclosure, the obtained catabolic filler filament is cooled to room temperature to obtain poly-L-lactic acid (PLA) compact catabolic filler thread, which is then wound onto a coil for later use. However, this disclosure is not limited to this; in some embodiments, the obtained catabolic filler filament may also be cooled in a cooling device. After obtaining the catabolic filler thread, it can be wound onto a coil for later use, or wound onto or stored in any component that is convenient for storage or use.

[0133] In exemplary embodiments of this disclosure, Figure 5 This is a flowchart illustrating a method for preparing a catabolic filler line according to an exemplary embodiment, such as... Figure 5 As shown, the preparation method of this disclosure may include the following steps:

[0134] S31: Dehydrate and dry poly-L-lactic acid at 65-110℃ for 16-24 hours.

[0135] For example, in one embodiment, the dehydration drying temperature can be around 75°C, and the dehydration drying time can be around 16 hours.

[0136] S32: Dry poly-L-lactic acid is spun at a temperature of 170-220℃, and after spinning, a decomposition and metabolism filler yarn is obtained.

[0137] S33: The catabolic filler wire is stretched and cooled to obtain the catabolic filler wire.

[0138] In exemplary embodiments of this disclosure, Figure 6 This is a flowchart illustrating a method for preparing a catabolic filler line according to an exemplary embodiment, such as... Figure 6 As shown, the preparation method of this disclosure may include the following steps:

[0139] S41: Dehydrate and dry poly-L-lactic acid at 65-110℃ for 16-24 hours.

[0140] S42: The dried poly-L-lactic acid is spun at a temperature of 170-220℃, and after spinning, a decomposition and metabolism filler yarn is obtained.

[0141] S43: Stretch the catabolic filler filament into a catabolic filler filament with a diameter of 100-120μm.

[0142] S44: Cool and shape the stretched catabolic filler filament into a catabolic filler thread.

[0143] In exemplary embodiments of this disclosure, Figure 7 This is a flowchart illustrating a method for preparing a catabolic filler line according to an exemplary embodiment, such as... Figure 7 As shown, the preparation method of this disclosure may include the following steps:

[0144] S51: Dehydrate and dry poly-L-lactic acid at a temperature of 65-110℃ for 16-24 hours.

[0145] S52: The dried poly-L-lactic acid is spun at a temperature of 190-220℃, and after spinning, a decomposition and metabolism filler yarn is obtained.

[0146] S53: Stretching the catabolic filler filament into a catabolic filler filament with a diameter of 100-120μm, including: stretching the catabolic filler filament into a catabolic filler filament with a diameter of 100-120μm at a temperature of 70-85℃, wherein the stretching speed is 2-4 times the filament output speed.

[0147] S54: Cool and shape the stretched catabolic filler filament into a catabolic filler thread.

[0148] The disclosed decomposition and metabolic filling thread can fill and tighten the skin through the action of the thread. At the same time, the lactic acid during degradation stimulates the subcutaneous tissue fibroblasts to restore their activity, thereby producing more collagen, elastin, and collagen fibers, making the skin more elastic in subsequent processes. In this process, the molecular structure of poly-L-lactic acid is gradually degraded and slowly hydrolyzed into lactic acid. The degradation product lactic acid is converted into pyruvate under the action of lactate dehydrogenase, and then enters the mitochondria to be completely oxidized and decomposed, generating CO2 and H2O, which are replaced by newly generated collagen. Compared with existing thread lifting materials, it has a longer-lasting and more obvious cosmetic effect.

[0149] Based on the same concept, this disclosure also provides a method for preparing a reagent kit. Figure 8 This is a flowchart illustrating a method for preparing a reagent kit according to an exemplary embodiment, such as... Figure 8 As shown, the preparation method of this disclosure may include the following steps:

[0150] S61: Place 50 grams of poly-L-lactic acid granules / powder into a drying oven for drying and dehydration for 24 hours.

[0151] S62: After drying, it is added to a melt spinning machine for spinning.

[0152] S63: Adjust the melting temperature of the spinning machine to 190-220 degrees Celsius, carry out spinning, and adjust the primary and secondary stretching to control the diameter at 100-120 μm.

[0153] S64: After the yarn is spun, cooled and shaped, it is cut into uniform lengths of 30mm.

[0154] S65: Insert the poly-L-lactic acid filament into a 29G-25mm needle, with the internal thread length of the needle tube being 15mm. Then, attach a foam fixing sleeve to the outside and fasten the needle protective sleeve.

[0155] Figure 9 This is a flowchart illustrating a method for preparing a reagent kit according to an exemplary embodiment, such as... Figure 9 As shown, the preparation method of this disclosure may include the following steps:

[0156] S71: Place 50 grams of poly-L-lactic acid granules / powder into a drying oven for drying and dehydration for 24 hours.

[0157] S72: After drying, it is added to a melt spinning machine for spinning.

[0158] S73: Adjust the melting temperature of the spinning machine to 190-220 degrees Celsius, carry out spinning, and adjust the primary and secondary stretching to control the diameter at 100-120 μm.

[0159] S74: After the yarn is spun, cooled and shaped, it is cut into uniform lengths of 55mm.

[0160] S75: Insert the poly-L-lactic acid filament into a 29G-38mm needle. The internal thread length of the needle tube is 30mm, and the external thread length is 25mm. Then, attach a thread fixing sleeve to the outside and fasten the needle protective cap.

[0161] Based on actual weighing, for a 100µm diameter catabolic filler thread, the weight per centimeter is 0.2353mg. Assuming a standard 38mm needle is used, and the catabolic filler thread is 55mm long, with 30mm inside the needle and 25mm outside, each needle is equivalent to injecting 1.2942mg of poly-L-lactic acid into the tissue. If 120 38mm needles are used for facial injection under normal conditions, this equates to 155mg of poly-L-lactic acid, equivalent to one bottle of commercially available lyophilized poly-L-lactic acid powder (each bottle contains 150mg of poly-L-lactic acid).

[0162] If a 200µm diameter, same-length catabolic filler thread is used instead, the same 120 puncture injections can achieve the same injection volume as four vials of traditional facial rejuvenation injections (a cylinder with twice the diameter, the same length, and four times the volume). This allows for precise calculation of the total dosage over a given area using different thread diameters, lengths, and the number of puncture needles, achieving a level of precision and uniformity unattainable with traditional liquid injection methods. It also shortens preparation and operation time, controls side effects caused by uneven dosage, and significantly improves patient acceptance.

[0163] Example 1

[0164] This embodiment provides a poly-L-lactic acid (PLL) firming and decomposing filler thread, the active ingredient of which is poly-L-lactic acid with a molecular weight of 30,000 Da and a thread diameter of 100-120 μm.

[0165] The preparation method of the poly-L-lactic acid firming and metabolic filling thread provided in this embodiment includes the following steps:

[0166] Medical poly-L-lactic acid granules / powder were placed in a drying oven for drying and dehydration for 24 hours at a temperature of 16°C.

[0167] After drying, the fibers are fed into a melt spinning machine for spinning. The melt temperature of the spinning machine is adjusted to 190-220℃. The screw extrudes the fibers at room temperature. After extrusion, the fibers are stretched to obtain a diameter of 100-120μm, and then cooled and set. The spinning temperature can be 200-220℃.

[0168] This embodiment also provides a reagent kit, taking 1000 vials as an example, including:

[0169] 50g of medical-grade poly-L-lactic acid granules / powder with a molecular weight of 30,000 Da;

[0170] 1000 needle handles and needles, with the inner diameter of the needle tube ranging from 29G to 38mm;

[0171] 1000 foam balls;

[0172] The reagent kit is prepared as follows:

[0173] 50g of medical poly-L-lactic acid granules / powder were prepared into poly-L-lactic acid firming and decomposition filling lines using the preparation method provided in this embodiment, and then cut into line segments of uniform length of 40mm.

[0174] Insert the cut line segments into the needle tube, with one line segment corresponding to each needle; the length of the line segment left inside the needle should be 20-25mm.

[0175] Place a foam ball on the outer wall of the needle to hold the part of the line segment outside the needle in place, and then attach the needle protective cap to obtain the reagent kit.

[0176] Example 2

[0177] This embodiment provides a poly-L-lactic acid firming and decomposition filling line and a kit. The relevant parameters and manufacturing methods of both are basically the same as those in Embodiment 1. The difference is that the molecular weight of the medical poly-L-lactic acid particles / powder used is 40,000 Da.

[0178] Example 3

[0179] This embodiment provides a poly-L-lactic acid firming and decomposition filler line and a kit. The relevant parameters and manufacturing methods of both are basically the same as those in Embodiment 1. The difference is that the molecular weight of the medical poly-L-lactic acid particles / powder used is 50,000 Da.

[0180] Example 4

[0181] This embodiment provides a poly-L-lactic acid firming and decomposition filling line and a kit. The relevant parameters and manufacturing methods of both are basically the same as those in Embodiment 1. The difference is that the molecular weight of the medical poly-L-lactic acid particles / powder used is 60,000 Da.

[0182] Example 5

[0183] This embodiment provides a poly-L-lactic acid firming and decomposition filler line and a kit. The relevant parameters and manufacturing methods of both are basically the same as those in Embodiment 1. The difference is that the molecular weight of the medical poly-L-lactic acid particles / powder used is 70,000 Da.

[0184] Example 6

[0185] This embodiment provides a poly-L-lactic acid firming and decomposition filler line and a kit. The relevant parameters and manufacturing methods of both are basically the same as those in Embodiment 1. The difference is that the molecular weight of the medical poly-L-lactic acid particles / powder used is 80,000 Da.

[0186] Example 7

[0187] This embodiment provides a poly-L-lactic acid firming and decomposition filler line and a kit. The relevant parameters and manufacturing methods of both are basically the same as those in Embodiment 1. The difference is that the molecular weight of the medical poly-L-lactic acid particles / powder used is 90,000 Da.

[0188] Example 8

[0189] This embodiment provides a poly-L-lactic acid firming and decomposition filler line and a kit. The relevant parameters and manufacturing methods of both are basically the same as those in Embodiment 1. The difference is that the molecular weight of the medical poly-L-lactic acid particles / powder used is 100kDa.

[0190] Example 9

[0191] This embodiment provides a poly-L-lactic acid firming and decomposition filler line and a kit. The relevant parameters and manufacturing methods of both are basically the same as those in Embodiment 1. The difference is that the molecular weight of the medical poly-L-lactic acid particles / powder used is 110kDa.

[0192] Example 10

[0193] This embodiment provides a poly-L-lactic acid firming and decomposition filler line and a kit. The relevant parameters and manufacturing methods of both are basically the same as those in Embodiment 1. The difference is that the molecular weight of the medical poly-L-lactic acid particles / powder used is 130kDa.

[0194] Example 11

[0195] This embodiment provides a poly-L-lactic acid firming and decomposition filler line and a kit. The relevant parameters and manufacturing methods of both are basically the same as those in Embodiment 1. The difference is that the molecular weight of the medical poly-L-lactic acid particles / powder used is 150kDa.

[0196] The mechanical properties of the poly-L-lactic acid firming and decomposition filling lines provided in Examples 1 to 9 were tested respectively, and the results are shown in Table 1 below.

[0197] Table 1 shows a comparison of the mechanical properties of the poly-L-lactic acid firming and metabolic filling lines provided in Examples 1 to 9 at a hot plate temperature of 70°C and a hot plate temperature of 90°C.

[0198]

[0199] Table 2 shows a comparison of the mechanical properties of the poly-L-lactic acid firming and metabolic filling lines provided in Examples 1 to 9 at a hot plate temperature of 80°C and a hot plate temperature of 120°C.

[0200]

[0201] Based on the data in Tables 1 and 2, it can be seen that when the spinning temperature is 200-220°C, the molecular weight is between 60,000 and 80,000, the hot plate temperature is 80°C, and the hot plate temperature is 120°C, the tensile strength of PLLA yarn can reach a maximum of 337-364 MPa.

[0202] The catabolic filling thread disclosed herein not only has advantages such as minimal side effects and excellent filling effect, but also possesses superior tensile and shear strength. Considering the potential cutting and pulling actions during subsequent use, such tensile and shear strength broadens the applicability and improves the performance of the catabolic filling thread disclosed herein.

[0203] It is understood that the catabolic filling line provided in this disclosure includes hardware structures and / or software modules corresponding to each function in order to achieve the above-mentioned functions. In conjunction with the units and algorithm steps of the various examples disclosed in this disclosure, this disclosure can be implemented in hardware or a combination of hardware and computer software. Whether a function is executed by hardware or by computer software driving hardware depends on the specific application and design constraints of the technical solution. Those skilled in the art can use different methods to implement the described functions for each specific application, but such implementation should not be considered beyond the scope of the technical solutions of this disclosure.

[0204] It is understood that in this disclosure, "multiple" refers to two or more, and other quantifiers are similar. "And / or" describes the relationship between related objects, indicating that three relationships can exist. For example, A and / or B can represent: A alone, A and B simultaneously, and B alone. The character " / " generally indicates that the preceding and following related objects are in an "or" relationship. The singular forms "a," "the," and "the" are also intended to include the plural forms unless the context clearly indicates otherwise.

[0205] It is further understood that the terms "first," "second," etc., are used to describe various types of information, but this information should not be limited to these terms. These terms are only used to distinguish information of the same type from one another, and do not indicate a specific order or degree of importance. In fact, the expressions "first," "second," etc., are completely interchangeable. For example, without departing from the scope of this disclosure, first information can also be referred to as second information, and similarly, second information can also be referred to as first information.

[0206] It is further understood that the terms “center,” “longitudinal,” “lateral,” “front,” “rear,” “up,” “down,” “left,” “right,” “vertical,” “horizontal,” “top,” “bottom,” “inner,” and “outer,” etc., indicate the orientation or positional relationship based on the orientation or positional relationship shown in the accompanying drawings. They are only for the convenience of describing this embodiment and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, or be constructed and operated in a specific orientation.

[0207] It can be further understood that, unless otherwise specified, "connection" includes both direct connections where no other components exist between the two parties and indirect connections where other components exist between them.

[0208] It is further understood that although operations are described in a specific order in the accompanying drawings in the embodiments of this disclosure, this should not be construed as requiring these operations to be performed in the specific order or serial order shown, or requiring all of the shown operations to be performed to obtain the desired result. In certain environments, multitasking and parallel processing may be advantageous.

[0209] Other embodiments of this disclosure will readily occur to those skilled in the art upon consideration of the specification and practice of the invention disclosed herein. This application is intended to cover any variations, uses, or adaptations of this disclosure that follow the general principles of this disclosure and include common knowledge or customary techniques in the art not disclosed herein. The specification and examples are to be considered exemplary only, and the true scope and spirit of this disclosure are indicated by the following claims.

[0210] It should be understood that this disclosure is not limited to the precise structures described above and shown in the accompanying drawings, and various modifications and changes can be made without departing from its scope. The scope of this disclosure is limited only by the appended claims.

Claims

1. A reagent kit, characterized in that, include: The reagent kit body includes a syringe and a needle, wherein the first end of the needle is attached to the syringe; as well as The catabolic filler line includes a first segment and a second segment connected to each other, wherein at least a portion of the first segment is located inside the needle and at least a portion of the second segment is located outside the needle; The molecular weight of the poly-L-lactic acid in the first segment is different from that in the second segment. The segment with a relatively larger molecular weight of poly-L-lactic acid is located at the second end of the needle tip, which is the point where the needle tip is bent back. The catabolic filling line is made of poly-L-lactic acid, and the length of the catabolic filling line is 20-80 mm, and the diameter of the catabolic filling line is 90-200 μm. The molecular weight of the poly-L-lactic acid in the first segment is smaller than that in the second segment, and there is a connecting segment between the first segment and the second segment, the connecting segment being located inside the needle. The length of the connecting segment is 0.5-5mm; The kit also includes a fixation element, which is sleeved on the needle and used to fix the catabolic filling line; The distance between the fixing member and the second end of the needle is 5-10mm, and the second end is positioned opposite to the first end.

2. The reagent kit according to claim 1, characterized in that, The length of the needle is 20-50mm.

3. The reagent kit according to claim 2, characterized in that, The length of the needle is 35-40mm; The length of the catabolic filling line inside the needle is 28-33 mm, and the length of the catabolic filling line outside the needle is 10-28 mm.

4. The reagent kit according to claim 2, characterized in that, The length of the needle is 22-27 mm; The length of the catabolic filling line inside the needle is 15-20 mm, and the length of the catabolic filling line outside the needle is 5-20 mm.

5. The reagent kit according to claim 1, characterized in that, The catabolism filler line is colorless or pale white.

6. The reagent kit according to claim 2, characterized in that, The surface of the catabolism filler line is smooth.

7. The reagent kit according to claim 2, characterized in that, The tensile strength of the catabolic filler line is 25cN-45cN.

8. The reagent kit according to claim 2, characterized in that, The elongation of the catabolism filler line is 25%-40%.

9. The kit according to any one of claims 1 to 8, characterized in that, The kit also includes a seal, with the kit body and the catabolic filling line located inside the seal.

Images